The trial is positive. The decisive numbers are not public yet.
Merck and Moderna say their personalized mRNA treatment met its recurrence-free and distant-metastasis-free endpoints in a Phase 3 melanoma trial. Across X, that became a cancer-cure headline, a stock story and another argument about mRNA vaccines. The topline result is important, but it is not the full dataset.
- Observed threads
- 5
- Source clusters
- 4
- Observed
- Updated
What was tested
Intismeran is made for an individual patient's tumor and given with Keytruda after high-risk melanoma has been surgically removed. It is a treatment intended to reduce recurrence, not a preventive vaccine against developing melanoma.
What succeeded
The companies say the combination improved recurrence-free survival and distant-metastasis-free survival against Keytruda alone. That makes it a positive late-stage trial, but the announcement is still a topline result.
What remains unknown
No hazard ratios, absolute event counts or detailed safety results have been released from Phase 3, and no overall-survival benefit has been established. The companies say fuller results will come at a medical meeting.
Why the reaction split
Moderna's share price more than doubled while replies mixed genuine enthusiasm with disputes over the word 'first,' demands for independent scrutiny and COVID-era distrust of mRNA technology. Those reactions do not all address the same claim.